$TIL News

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Instil Bio Q4 Adj. EPS $(0.97) Beats $(2.03) Estimate

HC Wainwright & Co. Downgrades Instil Bio to Neutral

Instil Bio Pulls Plug On Lead Drug Development

Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco

Instil Bio shares are trading lower after the company announced the company's subsidiary, Axion Bio, discontinued clinical development of AXN-2510 and that Axion and ImmuneOnco Biopharmaceuticals have entered into an agreement terminating their license and collaboration agreement for AXN-2510 and AXN-27M.

Instil Bio shares are trading lower after the company announced the company's subsidiary, Axion Bio, discontinued clinical development of AXN-2510 and that Axion and ImmuneOnco Biopharmaceuticals have entered into an agreement terminating their license and collaboration agreement for AXN-2510 and AXN-27M.

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

Instil Bio's Axion Subsidiary Ends AXN-2510 Clinical Development And Terminates License And Collaboration Agreement With ImmuneOnco

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Instil Bio Q3 Adj. EPS $(1.75) Beats $(2.35) Estimate

HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $125 Price Target

Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)

Instil Bio Says ImmuneOnco Biopharma Presents Preliminary Efficacy And Safety Data Of '2510 As Monotherapy In Phase 1 Study Of Patients In China With Previously Treated Sq-NSCLC At 2025 WCLC

Instil Bio, Inc. (NASDAQ:TIL) is definitely on the radar of institutional investors who own 36% of the company

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Instil Bio Q2 Adj. EPS $(2.88) Misses $(2.50) Estimate, Cash, Cash Equivalents, Restricted Cash, Marketable Securities And Long-term Investments Of $103.6M Will Enable The Company To Fund Its Operating Plan Beyond 2026

ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China